Salma Jabbour, M.D. Professor & Vice Chair of Clinical Research and Faculty Development

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Merck & Co, Inc
    Topic:
    radiotherapy/lung ca
    Date added:
    11/28/2022
    Date updated:
    11/27/2022
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Radialogica
    Topic:
    radiotherapy
    Date added:
    11/28/2022
    Date updated:
    11/27/2022
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Advarra
    Topic:
    lung ca
    Date added:
    11/28/2022
    Date updated:
    11/27/2022
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Novocure
    Topic:
    brain tumors
    Date added:
    11/28/2022
    Date updated:
    11/27/2022
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    IMX Medical
    Topic:
    reviewer
    Date added:
    11/28/2022
    Date updated:
    11/27/2022
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Merck & Co, Inc
    Topic:
    research
    Date added:
    11/28/2022
    Date updated:
    11/27/2022
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Beigene
    Topic:
    research
    Date added:
    11/28/2022
    Date updated:
    11/27/2022
Return to 2023 Annual Symposium For Evolving Therapies and Drug Development in Oncology: Targeted therapy, immunotherapy and beyond